We create a future.
For medical cannabis throughout Europe
European
We will engage in all european markets with a legal basis for medical cannabis.
Research based
We are a researching pharmaceutical company and focus on scientific innovation to become a global leader.
Natural
We push towards natural alternatives with cannabinoid therapies to give doctors and patients more choices.
Ask a question
If you would like to become our partner and still have some questions click here to send us your enquiry
Partnerships
Our Mission
Farmako GmbH is a research-based pharmaceutical company. Traditional research on pharmaceutical products has produced countless revolutions in the past century that have improved the lives of billions of people. Since the 1920s, however, research and development of pharmaceutical products based on the cannabis plant
Farmako is ready to drive this transformation worldwide.
Our Goals
Farmako wants to become a vertically integrated leader in every European country that has created a legal basis for medical cannabis. Cannabinoid therapies will change the pharmaceutical industry worldwide. We plan to drive this transformation with a high standard of commitment to our coworkers, our products and our speed. We are the first European company in the cannabis industry to focus on innovation through research and development. So that doctors, patients and pharmacists have more choices for the best possible therapy.
Farmako only hires the best to meet this demand. If you think you are one of them click here to apply.
Europe is changing. And we help naturally.
Many European countries are opening their health care systems to cannabinoid therapies. The legal basis is changing rapidly. In a few years, Europe will be home to the biggest number of patients worldwide. We aim to be active in every country that initiates this change.
million people
in Europe are waiting for new treatments and improved natural drugs.
billion €
Total healthcare expenditure in European Union Member States alone.
billion €
is the estimated market size for medical cannabis in Europe by 2028.
Research and Development
We are leading the change to natural alternatives
Application areas
Cannabinoid therapies can be used for a number of recognized indications. The research of further fields of application is still in its infancy – we support the change.
Development of alternative medicines
Products from the cannabis plant are a natural remedy. We conduct research on products that can be derived from those natural ingredients.
New processes
We are researching new methods for the safe production and processing of pharmaceutical products based on the cannabis plant.
Medical trials
We conduct active research with patients and doctors to ensure the viability of cannabis-based pharmaceutical solutions.
Alternative production of active ingredients
In the cannabis plant there are a number of cannabinoids and terpenes that have a pharmaceutical effect. We are researching ways to produce these drugs in alternative ways.
Our products
As a pharmaceutical wholesaler under German regulation, Farmako is not allowed to present or promote products.
For this reason, we can only give qualified specialists an insight into our products. If you are a doctor or pharmacist, please register in our partner area.
Join our team!
We need pragmatic problem solvers. Think fast, act fast people who are hungry for performance that pays.
Our Patents
We are a research-based pharmaceutical company. Our team consists of distinguished experts who are developing patents to establish pharmaceutical cannabis in health care.
Patrick Schmitt, the leader of our research and development, is supported by Prof.
Subscribe to our newsletter to be the first to be informed!
Followed by more
We continue to drive change. Our research
and development will continue to push forward in 2019.
Our Patents
We are a research-based pharmaceutical company. Our team consists of distinguished experts who are developing patents to establish pharmaceutical cannabis in health care.
Patrick Schmitt, the leader of our research and development, is supported by Prof.
Subscribe to our newsletter to be the first to be informed!
Followed by more
We continue to drive change. Our research
and development will continue to push forward in 2019.
Join our team!
We need pragmatic problem solvers. Think fast, act fast people who are hungry for performance that pays.
Our Founding Team
Our team displays a unique blend of experience with medical cannabis, entrepreneurship and scientific excellence.
Niklas Kouparanis
Niklas Kouparanis was the second employee and authorized officer of one of the currently leading German companies for medical cannabis. He shaped the industry as an established expert in the field, consultant to European governments, and supervisor to one of the first German-Canadian market entrances.
Sebastian Diemer
Sebastian is often described as one of Germany’s most successful founders. He has already successfully set up five companies, creating more than 1,000 jobs and raised over € 300 million in venture capital. His companies always pursued a global focus. He is founder and shareholder.
Mario Reichenbach
Mario studied Business Administration with a focus on Social Entrepreneurship. As a result, he started working in 2015 in the medical cannabis industry. After his internship in Colorado, he worked as one of the first employees at Europe’s first wholesaler for medicinal cannabis and as the Head of Business Development he was instrumental in providing medical cannabis in Europe.
Anna Kouparanis
Anna is a business development manager with experience in the biotech industry. Her most recent projects focused on revolutionizing the cancer diagnostics and treatment options together with FiZ, the Frankurt Innovation Center. At Farmako, she leads the European expansion.
Torsten Rössing
Torsten gained experience founding and managing a strategic PR consultancy. He is the regional chairman of the German Public Relations Association in Hessen, Rheinland-Pfalz and Saarland. At Farmako, he manages regulation and privacy. He is founder and shareholder.
Patrick Schmitt
Patrick Schmitt is a molecular biologist and certified expert in pharmaceuticals and nutritional supplements. As a sought-after expert he has many years of experience in product development, patenting, assessment and consulting. His work has found expression in more than 500 products on the market as well as a large number of patents. At Farmako, he heads the R & D department. He is co-founder and shareholder.
Prof. Dr. Bernhard Lieb
Bernhard is an adjunct professor at the Johannes Gutenberg University in Mainz. He researches and teaches at the Institute of Molecular Physiology and leads his own research group. He was involved in more than 50 publications and two patents. He is a state-approved pharmaceutical consultant, expert for genetical engineering and pharmaceutical products and he supports Farmako with his know-how as a scientific advisor.
Dr. med. Lena Müller
Lena is a medical doctor and a dentist. Since 2014, she works as a principal researcher in clinical trials and supervises clinical studies. She was a scholarship holder of the German Economy, is the winner of the scholarship “Medical Excellence” and the award winner “Filippas Engel 2014” for outstanding social commitment. She is responsible for the planning and execution of pharmaceutical studies at Farmako.
Marcus Ewald
Marcus gained experience founding and managing a strategic PR consultancy. He is the federal chairman of the Young Economic Council of Germany, he founded the Federal Blockchain Association and the Federal Association of AI. At Farmako, he directs public relations and public affairs. He is founder and shareholder.
Our worldwide focus
Farmako will be active in all markets that provide a legal basis for cananbinoid therapies. Those are the locations we are setting up.
